ArticleNMR in biomedicine2025
Insights Into CEST Contrast at 2 ppm in Enhancing and Nonenhancing Lesions From Glioma Patients Scanned at 7 T.
Article in NMR in biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Field strength-dependent sensitivity of chemical exchange saturation transfer: a methodological comparison of 3 Tesla and 7 Tesla in a clinical cohort.Brain communications · 2026Article
- Prediction of MGMT promoter methylation in glioblastoma and grade 4 astrocytoma using fluid-suppressed chemical exchange saturation transfer MRI and machine learning-based segmentation.Frontiers in oncology · 2026Article
- Insights Into CEST Contrast at 2 ppm in Enhancing and Nonenhancing Lesions From Glioma Patients Scanned at 7 T.NMR in biomedicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionChemical exchange saturation transfer (CEST) has been demonstrated to provide a noninvasive opportunity to image gliomas. Preclinical ultrahigh-field MRI studies have shown the value of the 2 ppm pool; however, in vivo studies in glioma patients are currently lacking. This study aimed to explore the 7 T MRI CEST contrast of the 2 ppm in gliomas and the tumor's different components.
methodsTwenty-one glioma patients treated at two tertiary referral centers for brain tumors in the Netherlands were scanned. Regions of interest were defined as contrast-enhancing (CE-lesion), nonenhancing (NE-lesion) tumor, and the contralateral normal-appearing white matter (CL NAWM). Magnetization transfer ratio asymmetry (MTRasym), Lorentzian difference (LD), spillover and magnetization transfer-corrected inverse difference (REX), and relaxation-compensated (AREX) were calculated for all regions of interest.
resultsThe 2 ppm CEST pool signal between tumor regions and normal-appearing tissue was found to be significantly different for all four CEST quantification methods (MTRasym p = 0.001; LD p < 0.001; REX p = 0.008; AREX p = 0.001). The CE and NE lesions showed significantly different 2 ppm pool CEST MTRasym (p = 0.034) and LD (p = 0.052). Significantly different 2 ppm CEST REX (p = 0.005) and AREX (p = 0.001) were found between the CL NAWM and the NE lesions.
conclusionsCEST 2 ppm pool contrast was distinctive between normal-appearing white matter, enhancing and nonenhancing tumor lesions, independently of the metric used. These findings suggest that the CEST pool at 2 ppm provides a valuable noninvasive contrast for imaging gliomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.